






PHARMACEUTICAL 2024

Northwest Biotherapeutics INC Rank 277 of 309

The relative strengths and weaknesses of Northwest Biotherapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Northwest Biotherapeutics INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Northwest Biotherapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 61%, being 152% points below the market average of 213%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	4,125	Assets	27,865
Cost of Goods Sold	0	Liabilities	74,920
Intangible Assets	626	Expenses	57,440
Liabilities, Current	45,204	Revenues	1,932
Liabilities, Non-Current	29,716	Stockholders Equity	-47,055
Other Assets	5,836	Net Income	-62,599
Other Compr. Net Income	-3,383	Comprehensive Net Income	-64,290
Other Expenses	0	BaseVar	86,316
Other Liabilities	0	ECR before LimitedLiability	-325%
Other Net Income	-7,091	Economic Capital Ratio	61%
Other Revenues	1,932		
Property and Equipment	17,278		
Research and Development	27,730		
Selling, General and Administrative Expense	29,710		